Evangelia Vlachou , Ronac Mamtani , Noah M. Hahn , Burles Johnson III , Jean Hoffman-Censits , Vivek Nimgaonkar
{"title":"接受恩福单抗维多汀治疗的患者在皮肤事件方面的种族差异","authors":"Evangelia Vlachou , Ronac Mamtani , Noah M. Hahn , Burles Johnson III , Jean Hoffman-Censits , Vivek Nimgaonkar","doi":"10.1016/j.clgc.2024.102090","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Enfortumab vedotin (EV) is an antibody–drug conjugate approved alone and in combination with pembrolizumab for advanced urothelial cancer (UC). EV-related-cutaneous-events (EVCEs) are common and rarely life-threatening. Black patients are frequently under-represented in oncology trials, and dermatologic conditions may vary with race.</p></div><div><h3>Methods</h3><p>Therefore, this retrospective analysis investigated differences in EVCE frequency between Black and White patients in an urban cohort (Johns Hopkins [JH]) and a US-based, nationwide electronic health record (EHR)-derived deidentified database (Flatiron Health [FH]) with sub-group analysis of those who had received prior pembrolizumab.</p></div><div><h3>Results</h3><p>The study included 12 Black patients in the JH Cohort (17.1%) and 24 Black patients in the FH Cohort (7.6%). In both cohorts, the frequency of EVCEs among Black patients was higher compared to White patients (JH: 66.7% vs. 33.3%; FH: 25.0% vs. 15.8%), though not statistically significant. In the larger FH Cohort EVCEs were significantly more common among Black compared to White patients treated with prior pembrolizumab (Odds Ratio [OR]: 4.76 [95%CI: 1.42, 15.95]) and recent pembrolizumab (within 90 days of EV initiation) (OR 9.00 [95%CI: 1.94, 41.66]).</p></div><div><h3>Conclusion</h3><p>This hypothesis-generating retrospective study, comprising the largest population of EV-treated Black patients reported to date, emphasizes the importance of attentiveness to EVCEs among Black patients, particularly with receipt of pembrolizumab.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin\",\"authors\":\"Evangelia Vlachou , Ronac Mamtani , Noah M. Hahn , Burles Johnson III , Jean Hoffman-Censits , Vivek Nimgaonkar\",\"doi\":\"10.1016/j.clgc.2024.102090\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Enfortumab vedotin (EV) is an antibody–drug conjugate approved alone and in combination with pembrolizumab for advanced urothelial cancer (UC). EV-related-cutaneous-events (EVCEs) are common and rarely life-threatening. Black patients are frequently under-represented in oncology trials, and dermatologic conditions may vary with race.</p></div><div><h3>Methods</h3><p>Therefore, this retrospective analysis investigated differences in EVCE frequency between Black and White patients in an urban cohort (Johns Hopkins [JH]) and a US-based, nationwide electronic health record (EHR)-derived deidentified database (Flatiron Health [FH]) with sub-group analysis of those who had received prior pembrolizumab.</p></div><div><h3>Results</h3><p>The study included 12 Black patients in the JH Cohort (17.1%) and 24 Black patients in the FH Cohort (7.6%). In both cohorts, the frequency of EVCEs among Black patients was higher compared to White patients (JH: 66.7% vs. 33.3%; FH: 25.0% vs. 15.8%), though not statistically significant. In the larger FH Cohort EVCEs were significantly more common among Black compared to White patients treated with prior pembrolizumab (Odds Ratio [OR]: 4.76 [95%CI: 1.42, 15.95]) and recent pembrolizumab (within 90 days of EV initiation) (OR 9.00 [95%CI: 1.94, 41.66]).</p></div><div><h3>Conclusion</h3><p>This hypothesis-generating retrospective study, comprising the largest population of EV-treated Black patients reported to date, emphasizes the importance of attentiveness to EVCEs among Black patients, particularly with receipt of pembrolizumab.</p></div>\",\"PeriodicalId\":10380,\"journal\":{\"name\":\"Clinical genitourinary cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical genitourinary cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1558767324000612\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324000612","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
导读:恩福妥单抗维多汀(EV)是一种抗体药物结合物,已被批准单独或与彭博利珠单抗联合用于晚期尿路上皮癌(UC)的治疗。与 EV 相关的切肤事件(EVCE)很常见,但很少危及生命。黑人患者在肿瘤试验中的代表性往往不足,而且皮肤病可能因种族而异。因此,这项回顾性分析调查了城市队列(约翰霍普金斯大学[JH])和美国全国范围内电子健康记录(EHR)衍生的去识别数据库(Flatiron Health [FH])中黑人和白人患者的EVCE频率差异,并对既往接受过pembrolizumab治疗的患者进行了亚组分析。在两个队列中,黑人患者发生 EVCE 的频率均高于白人患者(JH:66.7% 对 33.3%;FH:25.0% 对 15.8%),但无统计学意义。在更大的 FH 队列中,与白人患者相比,黑人患者中发生 EVCE 的比例明显更高(Odds Ratio [OR]:4.76 [95%CI:1.42, 15.95]),最近接受过彭博利珠单抗治疗(EV 开始后 90 天内)的患者中发生 EVCE 的比例也更高(OR 9.00 [95%CI:1.94, 41.66])。结论这项产生假设的回顾性研究是迄今为止报告的接受过EV治疗的黑人患者人数最多的一项研究,它强调了关注黑人患者EVCEs的重要性,尤其是在接受pembrolizumab治疗时。
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin
Introduction
Enfortumab vedotin (EV) is an antibody–drug conjugate approved alone and in combination with pembrolizumab for advanced urothelial cancer (UC). EV-related-cutaneous-events (EVCEs) are common and rarely life-threatening. Black patients are frequently under-represented in oncology trials, and dermatologic conditions may vary with race.
Methods
Therefore, this retrospective analysis investigated differences in EVCE frequency between Black and White patients in an urban cohort (Johns Hopkins [JH]) and a US-based, nationwide electronic health record (EHR)-derived deidentified database (Flatiron Health [FH]) with sub-group analysis of those who had received prior pembrolizumab.
Results
The study included 12 Black patients in the JH Cohort (17.1%) and 24 Black patients in the FH Cohort (7.6%). In both cohorts, the frequency of EVCEs among Black patients was higher compared to White patients (JH: 66.7% vs. 33.3%; FH: 25.0% vs. 15.8%), though not statistically significant. In the larger FH Cohort EVCEs were significantly more common among Black compared to White patients treated with prior pembrolizumab (Odds Ratio [OR]: 4.76 [95%CI: 1.42, 15.95]) and recent pembrolizumab (within 90 days of EV initiation) (OR 9.00 [95%CI: 1.94, 41.66]).
Conclusion
This hypothesis-generating retrospective study, comprising the largest population of EV-treated Black patients reported to date, emphasizes the importance of attentiveness to EVCEs among Black patients, particularly with receipt of pembrolizumab.
期刊介绍:
Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.